Frederick G Vogt Iovance Biotherapeutics, Inc. (IOVA) insider trading activity

Frederick G Vogt is Interim CEO & General Counsel of IOVANCE BIOTHERAPEUTICS, INC.. Currently has a direct ownership of 404,604 shares of IOVA, which is worth approximately $704,010. The most recent transaction as insider was on Jun 02, 2025, when has been sold 22,127 shares (Common Stock) at a price of $1.76 per share, resulting in proceeds of $38,943. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 405K

15.72% 3M change

174.63% 12M change

Total Value Held $704,010

Frederick G Vogt Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 02 2025	SELL Payment of exercise price or tax liability	$38,943 $1.76 p/Share	22,127 Reduced 5.19%	404,604 Common Stock
Jun 02 2025	BUY Exercise of conversion of derivative security	-	52,085 Added 10.88%	426,731 Common Stock
May 14 2025	BUY Open market or private purchase	$42,250 $1.69 p/Share	25,000 Added 6.26%	374,646 Common Stock
Mar 03 2025	SELL Payment of exercise price or tax liability	$385,468 $4.04 p/Share	95,413 Reduced 21.44%	349,646 Common Stock
Mar 03 2025	BUY Exercise of conversion of derivative security	-	223,943 Added 33.47%	445,059 Common Stock
Jan 14 2025	SELL Payment of exercise price or tax liability	$58,634 $5.89 p/Share	9,955 Reduced 4.31%	221,116 Common Stock
Jan 14 2025	BUY Exercise of conversion of derivative security	-	20,835 Added 8.27%	231,071 Common Stock
Dec 02 2024	SELL Payment of exercise price or tax liability	$40,143 $9.07 p/Share	4,426 Reduced 2.06%	210,236 Common Stock
Dec 02 2024	BUY Exercise of conversion of derivative security	-	10,417 Added 4.63%	214,662 Common Stock
Oct 14 2024	SELL Payment of exercise price or tax liability	$86,474 $9.77 p/Share	8,851 Reduced 4.15%	204,245 Common Stock
Oct 14 2024	BUY Exercise of conversion of derivative security	-	20,834 Added 8.91%	213,096 Common Stock
Sep 03 2024	SELL Payment of exercise price or tax liability	$264,078 $10.85 p/Share	24,339 Reduced 11.24%	192,262 Common Stock
Sep 03 2024	BUY Exercise of conversion of derivative security	-	57,292 Added 21.26%	212,175 Common Stock
Jul 15 2024	SELL Payment of exercise price or tax liability	$76,826 $8.68 p/Share	8,851 Reduced 5.26%	159,309 Common Stock
Jul 15 2024	BUY Exercise of conversion of derivative security	-	20,835 Added 11.02%	168,160 Common Stock
Jun 03 2024	SELL Payment of exercise price or tax liability	$37,045 $8.37 p/Share	4,426 Reduced 2.92%	147,325 Common Stock
Jun 03 2024	BUY Exercise of conversion of derivative security	-	10,417 Added 6.42%	151,751 Common Stock
Apr 15 2024	SELL Payment of exercise price or tax liability	$105,238 $11.89 p/Share	8,851 Reduced 5.89%	141,334 Common Stock
Apr 15 2024	BUY Exercise of conversion of derivative security	-	20,834 Added 12.18%	150,185 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$194,175 $16.96 p/Share	11,449 Reduced 8.13%	129,351 Common Stock
Mar 04 2024	BUY Exercise of conversion of derivative security	-	41,662 Added 22.83%	140,800 Common Stock
Jan 16 2024	SELL Payment of exercise price or tax liability	$54,656 $8.37 p/Share	6,530 Reduced 6.18%	99,138 Common Stock
Jan 16 2024	BUY Exercise of conversion of derivative security	-	20,834 Added 16.47%	105,668 Common Stock
Oct 16 2023	SELL Payment of exercise price or tax liability	$31,598 $3.57 p/Share	8,851 Reduced 9.45%	84,834 Common Stock
Oct 16 2023	BUY Exercise of conversion of derivative security	-	20,835 Added 18.19%	93,685 Common Stock

FGV

Frederick G Vogt

Interim CEO & General Counsel

San Carlos, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IOVA shares.

Notify only if

Value

Insider Trading

Get notified when an Iovance Biotherapeutics, Inc. insider buys or sells IOVA shares.

Notify only if

Operation

Value

Type

News

Receive news related to IOVANCE BIOTHERAPEUTICS, INC.

Track Activities on IOVA

Account